

# Michael S. Kelly

## Pharm.D., FNLA, BCACP, CDCES, CLS

*Assistant Professor* – Department of Pharmacy practice  
Chapman University School of Pharmacy  
Rinker Health Science Campus  
Irvine, CA 92618

**Email:** mkelly@chapman.edu

**Office:** (714) 516-5423

### Education and Professional Training

---

2015-2016	ASHP Accredited Ambulatory Care/Family Medicine PGY-2 Residency University of Colorado Anschutz Medical Campus Residency Director: Joseph Saseen, Pharm.D., BCACP, BCPS
2014-2015	Ambulatory Care/Academia PGY-1 Residency Virginia Commonwealth University School of Pharmacy Residency Director: Evan Sisson, Pharm.D., MSHA, CDE
2010-2014	Doctor of Pharmacy (Pharm.D.) – <i>Magna Cum Laude</i> Virginia Commonwealth University School of Pharmacy Richmond, VA
2006-2009	Bachelor of Science Biochemistry/Biotechnology Grand Valley State University Allendale, MI

### Licensures and Certifications

---

2018-present	Clinical Lipid Specialist (CLS)
2017-present	Certified Diabetes Care and Education Specialist (CDCES)
2017-present	Advanced Practice Pharmacist- California (#10139)
2017-present	Lipid Management for Pharmacists Certificate; California Pharmacists Association (CPhA)
2016-present	Board Certified Ambulatory Care Pharmacist (#6150670)
2016-present	Registered Pharmacist, California (#76089)
2015-2016	University of Colorado Teaching Certificate
2014-present	Registered Pharmacist, Virginia (#0202213080)
2012-present	APhA Pharmacy-Based Immunization Delivery Certificate

### Professional Experience

---

2016-present	<b>Assistant Professor</b> Department of Pharmacy Practice Chapman University School of Pharmacy
2011-2014	<b>Pharmacy Intern</b> Rite-Aid Pharmacy Richmond, VA

## Awards and Honors

---

2019	Fellow of National Lipid Association (FNLA)
2017	Diversity and Inclusion Education Curricular Innovation Award (\$1,500) Chapman University
2017	Scholarly/Creative Activity Award (\$2,614) Chapman University
2014	Resident Travel Award ACCP Ambulatory Care PRN
2013	Rho Chi Honor Society
2012	Research Fellowship Award Virginia Commonwealth University School of Pharmacy

## Professional Membership

---

2018-present	American Association of Diabetes Educators (AADE)
2015-present	American College of Cardiology (ACC)
2015-present	National Lipid Association (NLA)
2014-present	American Association of Colleges of Pharmacy (AACP)
2013-present	American College of Clinical Pharmacy (ACCP)

## Professional Service Activities

---

### *Clinical Service*

2018-present	<b>Quality Performance Improvement</b> MemorialCare Medical Group Fountain Valley, CA
2016-present	<b>Clinical Pharmacist</b> MemorialCare Medical Group Long Beach, CA

### *University Service* (Chapman University School of Pharmacy)

2019-2020	<b>Co-Chair</b> , Steering Committee for ACPE on-site visit
2019-present	<b>Member</b> , Objective Structured Clinical Examination (OSCE) Committee
2017-2019	<b>Member</b> , Interprofessional Education Committee
2016-2019	<b>Member</b> , Assessment Committee
2016-2018	<b>Member</b> , Faculty Search Committee
2017-present	<b>Faculty Advisor</b> Hispanic Association of Pharmacists (HAP)
2016-2020	<b>Co-Advisor</b> , Career Development and Exploration Committee (CDEC)
2016-2019	<b>Student Success Advisor</b> , Class of 2019

## Professional Organization Service

### American Association of Colleges of Pharmacy

2017                      *Reviewer, 2018 AACP Distinguished Teaching Scholar Award*  
2017-2018              *Member, Council of Faculties- Junior Faculty Community*

### American College of Clinical Pharmacy

2019                      *Reviewer, ACSAP Dyslipidemia chapter (Cardiology Care 2020)*  
2019                      *Volunteer, ACSAP pilot tester (Pulmonology Care)*  
2018-present          *Member, Communication Committee; Ambulatory Care PRN*  
2017-present          *Volunteer, Curriculum Vitae and Letter of Intent Reviewer*  
2016-2018              *Member, Scholarly Activities Committee; Ambulatory Care PRN*

### National Lipid Association

2019                      *Therapeutics Committee Writing Group*  
2018-present          *Regional Representative, Pacific Lipid Association Regional Chapter*  
2018-2019              *Member, Media Relations Committee*

### American College of Cardiology

2019-present          *Member, California Cardiovascular Team Section*  
2018-present          *Member, Cardiovascular Management Section*

## Publications

---

*Peer-Reviewed Manuscripts (\* denotes pharmacy student)*

1.        Bucheit J, **Kelly MS**. An Overview of the ACC/AHA Recommendations on Cholesterol Management in People With Diabetes. *ADCES in Practice*. 2020;8(2):20-24.
2.        Board C, **Kelly MS**, Shapiro MD, Dixon DL. PCSK9 inhibitors in secondary prevention- an opportunity for personalized therapy. *J Cardiovasc Pharmacol*. 2020 Feb 14. [Epub ahead of print].
3.        **Kelly MS**, Lewis J, Huntsberry AM, \*Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. *Postgrad Med*. 2019 Jan;131(1):31-42.
4.        Sisson EM, Pamulapati L, Bucheit JD, **Kelly MS**, Dixon DL. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. *Pharmacotherapy*. 2018 Feb; 38(2):164-171.
5.        **Kelly MS**, Beavers C, Bucheit JD, Sisson EM, Dixon DL. Pharmacological Approaches For the Management of Patients with Moderately Elevated Triglycerides (150-499 mg/dL). *J Clin Lipidol*. 2017;11:872-879.
6.        Baker WL, Buckley LF, **Kelly MS**, Bucheit JD, Parod ED, Brown R, Carbone S, Dixon DL. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic-Review and Meta-Analysis. *J Am Heart Assoc*. 2017; 6(5):1-12

7. **Kelly MS**, Saseen JJ, Mars JC. Assessment of achieved systolic blood pressure in newly treated hypertensive patients aged 60-79 years before and after Eight Joint National Committee recommendations. *Ther Adv Cardiovasc Dis*. 2017;11(2):63-71.
8. Dixon DL, Dunn SP, **Kelly MS**, McIlarky TR, Brown RE. Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. *Pharmacotherapy*. 2016;36(2):230-236.
9. **Kelly MS**, Moczygemba LR, Gatewood SS. Concordance of pharmacist assessment of medication nonadherence with a self-report medication adherence scale. *J Pharm Pract*. 2014; Oct 13. [online]

#### *Book Chapters*

1. Beavers CJ, **Kelly MS**. Dyslipidemia. In: Murphy JE, Lee MW, eds. *Pharmacotherapy Self-Assessment Program, 2019 Book 1. Cardiology*. Lenexa, KS: American College of Clinical Pharmacy, 2019:31-52.

#### *Abstracts From Conference Proceedings*

1. Bhagat S, Khaddage S, Baker W, Salgado T, Koenig R, **Kelly M**, Dixon D. Impact of pharmacist interventions on reducing low-density lipoprotein cholesterol levels: A systematic review and meta-analysis. *J Am Coll Clin Pharm*. 2020;3:362.
2. **Kelly M**, Norman JL, Oung A, Wettergreen S, Saseen JJ, Vande Griend J. A population health intervention by PGY2 pharmacy residents to optimize medication management in patients with atherosclerotic cardiovascular disease (ASCVD). *Pharmacotherapy*. 2016; 36(12): e288.
3. Dixon DL, Sisson EM, Parod E, **Kelly M**. Nighttime dosing of amlodipine vs. lisinopril in non-dipping African Americans-an interim analysis. *AJPE*. 2016; 80 (5) Article S2. 119.
4. **Kelly M**, Dixon DL. Interim Results from a Cardiologist-Pharmacist Collaboration to Improve Blood Pressure in an Ambulatory Cardiology Clinic. *Pharmacotherapy*. 2013; 33(10): e271.

#### *Other Publications*

1. Andraos J, Zeiger A, **Kelly MS**. Is dapagliflozin adaptable to treating HFrEF in patients without diabetes? *iForumRx* 2019. Available at: [iforumrx.org](http://iforumrx.org)
2. **Kelly MS**. Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone? *Evidence-Based Practice*. 2017;20(9):E12. Available at: <https://journals.lww.com/ebp/Abstract/2017/09000/>
3. **Kelly MS**, Olson KL. New Evidence For Non-Statin Lipid-Lowering Medications. *LipidSpin*. 2016;14(1):16-17.
4. **Kelly MS**, Sisson EM. Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE. *iForumRx* 2015. Available at: <http://www.iforumrx.org/node/274>

#### *Continuing Education Programs*

1. Co-presenter. *Statin Intolerance: Diagnosis and Management*. VuMedi CME webinar. May 2017.

## Scholarship Activities

---

### *Grants*

2015-2016                      Dixon D (PI), **Kelly M** (Co-Investigator). Nighttime Dosing of Amlodipine versus Lisinopril in Non-Dipping African Americans. AACP New Investigator Award (\$10,000).

### *Journal Reviewer*

2020                      Pharmacotherapy  
2020                      Diabetes, Obesity and Metabolism  
2019                      American Journal of Cardiovascular Drugs  
2019                      Diabetes Metabolism Research and Reviews  
2015-present              Annals of Pharmacotherapy  
2015-present              Journal of Pharmacy Practice

### *Additional Reviewer Activities*

2017                      Tarascon Pharmacopoeia- *Endocrine and Metabolism section*  
2015-present              iForumRx Commentary

## Presentations

---

### *Oral Presentations*

1. **Kelly MS**. Population health models to improve cholesterol management. National Lipid Association (NLA) Fall Clinical Lipid Update. Minneapolis, MN. September 14, 2019.
2. Bucheit JD, **Kelly MS**. A practical approach to integrating the new dyslipidemia guidelines for patients with diabetes. American Association of Diabetes Educators (AADE) Annual meeting. Houston, TX. August 11, 2019
3. **Kelly M**, Lewis J. Ready, set, inject: Updates to Injectable Medications for Type 2 Diabetes. California Society of Health-System Pharmacists (CSHP) Seminar. Las Vegas, NV. October 28, 2017.
4. **Kelly M**. Retrospective assessment of achieved systolic blood pressure in newly treated hypertensive patients aged 60-79 years, before and after JNC 8 guideline update. Mountain States Residency Conference. Salt Lake City, UT. May 12, 2016.

### *Scientific Posters Presentations* (\* denotes pharmacy student)

1. \*Rabbani A, \*Ruiz H, **Kelly MS**. Interim Results of 24-hour Ambulatory Blood Pressure Monitoring Among Patients Seen in a Family Medicine Clinic. 2018 American College of Clinical Pharmacy (ACCP) Global Conference. Seattle, WA. October 22, 2018.
2. \*Dea L, \*Chau B, **Kelly M**. Evaluation of a Pharmacist-led Interdisciplinary Healthcare Team in Treating Patients With Uncontrolled Diabetes. California Pharmacists Association (CPhA) Western Pharmacy Exchange. San Diego, CA. April 13, 2018.
3. **Kelly M**, Dixon DL. Interim Results of a Cardiologist-Pharmacist Collaboration to Improve Blood Pressure in an Ambulatory Cardiology Clinic. Albuquerque, NM. October 14, 2013.

## Teaching Experience

---

### ***Chapman University School of Pharmacy***

#### *Course Coordinator*

2019	Pharmacist Care Lab 4 (1 credit lab-based course)
2019-2020	Self-Care Behaviors of Diabetes Mellitus elective (1 credit)
2017-2019	Interprofessional Education
2017	Advanced Cardio-metabolic Disease Management elective (1 credit)
2016-present	Endocrinology Therapeutics Module (4 credits)

#### *Lecturer*

2017	Advanced Health Education Experience (Osteoporosis and Thyroid)
2017	Cardiology (Hypertension and Dyslipidemia)

#### *Facilitator*

2017-present	Health Care Delivery II
2017-2018	Stroke Boot Camp

#### *Experiential Preceptor*

2017-present	Advanced Pharmacy Practice Experience, Ambulatory Care
2017-2018	Introductory Pharmacy Practice Experience

### ***Chapman University – Physician Assistant Studies***

#### *Lecturer*

2019	Clinical Management of Lipid Disorders
2019	Clinical Management of Diabetes Mellitus
2019-2020	Pharmacology and Pharmacotherapy of Dyslipidemia
2018	Clinical Management of Diabetes Mellitus
2018-present	Interprofessional Education